Bertha this is also consistent with what they have been saying on the last couple of conference calls. Hemodefend should be a relatively straightforward shorter trial which can hopefully be completed without a lot of the complications and slow recruitment you have seen with the REFRESH trial.
Hopefully we will hear in the next few weeks/before year end some news about the acceptance of the IDE. There is also the potential for some news around a partnership for Hemodefend
"I think our primary goal for the United States is not to do this alone. It is to partner this with a major player in the blood transfusions space. And we have had discussions with all of the major players in the past." Dr. Chan
News 
Market Data 
Discover 
AI
